Article
作者: Simakina, Elena N ; Blinow, Andrew A ; Tikhomolova, Elena G ; Azarova, Valeria N ; Papazova, Natalia A ; Sitdekov, Tagir A ; Ilin, Alexey P ; Ivashchenko, Andrey A ; Dmitriev, Kirill A ; Yakubova, Elena V ; Pavlikova, Elena P ; Kravchenko, Dmitry V ; Gordeev, Ivan G ; Ivachtchenko, Alexandre V ; Karapetian, Ruben N ; Smolyarchuk, Elena A ; Vostokova, Natalia V ; Lomakin, Nikita V ; Merkulova, Elena A ; Savchuk, Nikolay P ; Egorova, Alina N
Abstract:In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within 4 days, and was safe and well-tolerated.Clinical Trials Registration. NCT04434248.
